Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle A Detry

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|April 20, 2022
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trialJienchi Dorward, Ly-Mee Yu, Gail Hayward, et al.
The Lancet. Respiratory Medicine|July 30, 2021
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialChristopher C Butler, Ly-Mee Yu, Jienchi Dorward, et al.
The Journal of Infection|March 2, 2024
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomesGail Hayward, Ly-Mee Yu, Paul Little, et al.
Journal of the American College of Cardiology|May 20, 2026
Vagal Nerve Stimulation in Patients With Heart Failure and Reduced Ejection Fraction: The ANTHEM-HFrEF TrialMarvin A Konstam, James E Udelson, Douglas L Mann, et al.
The Journal of Infection|August 31, 2024
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomesFd Richard Hobbs, Oghenekome A Gbinigie-Thompson, Milensu Shanyinde, et al.
Neurocritical Care|September 14, 2021
Hypothermia for Patients Requiring Evacuation of Subdural Hematoma: A Multicenter Randomized Clinical TrialGeorgene W Hergenroeder, Shoji Yokobori, Huimahn Alex Choi, et al.
Lancet (London, England)|August 13, 2021
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialLy-Mee Yu, Mona Bafadhel, Jienchi Dorward, et al.
The Lancet. Neurology|January 25, 2025
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trialKristy K L Coleman, Scott Berry, Jeffrey Cummings, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|April 20, 2022
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trialJienchi Dorward, Ly-Mee Yu, Gail Hayward, et al.
The Lancet. Respiratory Medicine|July 30, 2021
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialChristopher C Butler, Ly-Mee Yu, Jienchi Dorward, et al.
The Journal of Infection|March 2, 2024
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomesGail Hayward, Ly-Mee Yu, Paul Little, et al.
Journal of the American College of Cardiology|May 20, 2026
Vagal Nerve Stimulation in Patients With Heart Failure and Reduced Ejection Fraction: The ANTHEM-HFrEF TrialMarvin A Konstam, James E Udelson, Douglas L Mann, et al.
The Journal of Infection|August 31, 2024
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomesFd Richard Hobbs, Oghenekome A Gbinigie-Thompson, Milensu Shanyinde, et al.
Neurocritical Care|September 14, 2021
Hypothermia for Patients Requiring Evacuation of Subdural Hematoma: A Multicenter Randomized Clinical TrialGeorgene W Hergenroeder, Shoji Yokobori, Huimahn Alex Choi, et al.
Lancet (London, England)|August 13, 2021
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialLy-Mee Yu, Mona Bafadhel, Jienchi Dorward, et al.
The Lancet. Neurology|January 25, 2025
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trialKristy K L Coleman, Scott Berry, Jeffrey Cummings, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Pageof 5